Zymeworks (ZYME) 2026 Bloom Burton & Co. Healthcare Investor Conference summary

Industry trends and sector outlook

• Biotech sector is experiencing renewed recognition for innovation, with increased M&A activity and rising valuations, as evidenced by the XBI index reaching a five-year high.

• Companies are benefiting from a shift in investor sentiment, with more credit given to recent scientific advancements.

Strategic business model evolution

• Transitioned from a computational platform to developing proprietary molecules, leading to the first approved drug and a new revenue stream.

• Revenue from partnered product sales is stable and long-term, enabling self-funding and reducing reliance on equity financing.

• Accessed non-dilutive financing by leveraging future royalty streams, supporting R&D, acquisitions, and shareholder returns.

Financial position and capital allocation

• Strong cash position with $271 million, excluding $250 million in royalty proceeds, ensures sustainability without cash runway concerns.

• Focus on capital allocation to enhance shareholder value, with no immediate need for a commercial sales force.

• Strategy includes investing in R&D, making acquisitions, and returning capital to shareholders.